Akriveia Therapeutics' Aklusion(TM) Platform for Tumor-Targeting Cancer Immunotherapies to be Featured in Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting
PRINCETON, N.J., Nov. 7, 2017 /PRNewswire/ -- Akriveia Therapeutics Inc., an immuno-oncology focused biotechnology company, today announced its Aklusion(TM) platform for tumor-targeting cancer immunotherapies will be featured in a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 32(nd) Annual Meeting, November 10-12, 2017, at Gaylord National Hotel & Convention Center in National Harbor, MD.
The poster's authors include scientists from the laboratories of Professor John Williams of the Beckman Research Institute at the City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, along with Dr. Margaret Karow, Senior Vice President of Drug Discovery and Preclinical Development at Akriveia Therapeutics.
Information about the poster presentation is:
Poster Title: Rational Design of Immuno-Oncology Biologics with Improved Safety and Efficacy
Poster Number: P466
Poster Session: Saturday November 11(th) 12:30pm-2:00pm and 6:30pm-8:00pm
About Akriveia Therapeutics
Akriveia Therapeutics is pursuing the discovery and development of next generation cancer immunotherapies. Akriveia believes its new agents offer the promise of a more efficacious and safer approach to harness a patient's own immune system to fight cancer. Akriveia was founded on the pioneering work of Professor John Williams at City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, experts in the fields of bioengineering and cancer therapeutic discovery. The company is backed by leading life science investor FPrime Capital Partners.
SOURCE Akriveia Therapeutics
